Abstract | AIMS:
Tropomyosin receptor kinase (TRK)-targeted therapies represent an important therapeutic option for patients with advanced solid tumours harbouring neurotrophin receptor kinase (NTRK) gene fusions. However, NTRK fusions are rare in common adult carcinomas, and systematic approaches to screening for these alterations are lacking. Pan-TRK immunohistochemistry (IHC) has been proposed as one method to screen for NTRK fusion-positive tumours. Reflexive testing strategies have been endorsed for several IHC-based biomarkers, and thus offer a convenient and low-cost entry point to incorporate pan-TRK screening. METHODS AND RESULTS: CONCLUSION: The clinical impact of pan-TRK IHC 'piggybacking' on existing reflexive testing strategies in surgical pathology appears negligible. Carcinomas may rarely show high-level pan-TRK expression in the absence of an underlying NTRK fusion event.
|
Authors | Lynette M Sholl, Mei Zheng, Valentina Nardi, Jason L Hornick |
Journal | Histopathology
(Histopathology)
Vol. 79
Issue 2
Pg. 260-264
(Aug 2021)
ISSN: 1365-2559 [Electronic] England |
PMID | 33682174
(Publication Type: Journal Article)
|
Copyright | © 2021 John Wiley & Sons Ltd. |
Chemical References |
- Biomarkers, Tumor
- Receptor Protein-Tyrosine Kinases
|
Topics |
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(analysis)
- Early Detection of Cancer
(methods)
- Female
- Gene Fusion
- Genetic Testing
- Humans
- Immunohistochemistry
(methods)
- Male
- Middle Aged
- Neoplasms
(genetics, pathology)
- Receptor Protein-Tyrosine Kinases
(analysis, genetics)
- Sequence Analysis, RNA
|